The Library
Prostate radiotherapy for men with metastatic disease : a new comparison in the systemic therapy in advancing or metastatic prostate cancer : evaluation of drug efficacy (STAMPEDE) trial
Tools
Tools
Tools
Parker, Christopher C., Sydes, Matthew R., Mason, Malcolm D., Clarke, Noel W., Aebersold, Daniel, De Bono, Johann S., Dearnaley, David P., Ritchie, A. W. S., Russell, J. Martin, Thalmann, George, Parmar, Mahesh K. B. and James, Nicholas D. (2013) Prostate radiotherapy for men with metastatic disease : a new comparison in the systemic therapy in advancing or metastatic prostate cancer : evaluation of drug efficacy (STAMPEDE) trial. BJU International, 111 (5). pp. 697-699. doi:10.1111/bju.12087
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1111/bju.12087
Abstract
Many patients presenting with metastatic prostate cancerask whether they should have treatment to the prostateitself in addition to their hormone therapy. This question isincreasingly common and there is a growing sense thatthese inquiring patients may be on to something, asinternational randomised controlled trials have now provena survival benefit to adding radiotherapy (RT) to hormonetherapy for men with locally advanced disease [1,2]. Fromearly in 2013, the Systemic Therapy in Advancing orMetastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) trial will investigate whether treatmentdirec ted against the primary tumour might indeed retardmetastatic progression and thereby prolong survival bytesting the role of RT-to-the-prostate in men presentingwith metastatic disease
| Item Type: | Journal Article | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Cancer Research Unit | ||||||||||
| Library of Congress Subject Headings (LCSH): | Prostate -- Cancer, Metastasis | ||||||||||
| Journal or Publication Title: | BJU International | ||||||||||
| Publisher: | Wiley-Blackwell Publishing Ltd. | ||||||||||
| ISSN: | 1464-1603 | ||||||||||
| Official Date: | May 2013 | ||||||||||
| Dates: |
|
||||||||||
| Volume: | 111 | ||||||||||
| Number: | 5 | ||||||||||
| Number of Pages: | 3 | ||||||||||
| Page Range: | pp. 697-699 | ||||||||||
| DOI: | 10.1111/bju.12087 | ||||||||||
| Status: | Peer Reviewed | ||||||||||
| Publication Status: | Published | ||||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||||
| Funder: | Medical Research Council (Great Britain) (MRC), Cancer Research UK (CRUK), Novartis (Firm), Pfizer Ltd., Sanofi Aventis (Firm), Janssen Pharmaceutical Ltd., National Cancer Research Institute (NCRI) | ||||||||||
| Grant number: | CRUK/06/019 (CRUK) |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
